Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the ...

EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label expansions for macular edema and extended dosing intervals. Management believes these developments ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Regeneron (NASDAQ: REGN )'s flagship eye drug franchise, consisting of EYLEA HD and EYLEA, saw U.S. net sales increase 2% to ...

Reports Q4 revenue $3.79B, consensus $3.75B. “Regeneron’s (REGN) financial and commercial strength allows for continued investment in our ...

KB Home Chairman and CEO Jeffrey Mezger said the company, based in the Westwood neighborhood of Los Angeles, is fully operational, though some of its employees have been affected by the fires.

Emma Wen, a senior at Great Neck North High School, is researching more effective ways to fight pancreatic cancer.

We recently published a list of 10 Best Falling Stocks to Invest in Right Now. In this article, we are going to take a look ...

A senior at the Hackley School in Tarrytown was named a finalist in the prestigious Regeneron Science Talent Search. Vivek ...

Regeneron and Society for Science selected The Frazer School senior Sophia Rong as a finalist in the Regeneron Science Talent Search 2025. Rong was the only ...